<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Medicine</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/20E7CBC8-0336-48E6-B199-76F5B2FDB0C0"><gtr:id>20E7CBC8-0336-48E6-B199-76F5B2FDB0C0</gtr:id><gtr:firstName>Julian</gtr:firstName><gtr:otherNames>Charles</gtr:otherNames><gtr:surname>Matthews</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C70A1EC0-6618-4AC5-BA85-32C5A00E96E7"><gtr:id>C70A1EC0-6618-4AC5-BA85-32C5A00E96E7</gtr:id><gtr:firstName>Charalampos</gtr:firstName><gtr:surname>Tsoumpas</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FB69D4A7-EC07-4538-8BD3-446B63A2E425"><gtr:id>FB69D4A7-EC07-4538-8BD3-446B63A2E425</gtr:id><gtr:firstName>Erica</gtr:firstName><gtr:surname>Yang</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2137E0A5-FF45-49FB-94BB-52C38B0AA555"><gtr:id>2137E0A5-FF45-49FB-94BB-52C38B0AA555</gtr:id><gtr:firstName>Claudia</gtr:firstName><gtr:surname>Prieto</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/59959528-6A0F-4764-A707-D89E56FB7AAD"><gtr:id>59959528-6A0F-4764-A707-D89E56FB7AAD</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>Jonathan</gtr:otherNames><gtr:surname>Reader</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/EF7495A9-B9E3-44A9-973E-FF3CB9C0D10D"><gtr:id>EF7495A9-B9E3-44A9-973E-FF3CB9C0D10D</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:otherNames>Robert</gtr:otherNames><gtr:surname>Arridge</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F5E50EC5-49B5-4282-A954-5C7BFC66B0AC"><gtr:id>F5E50EC5-49B5-4282-A954-5C7BFC66B0AC</gtr:id><gtr:firstName>Kris</gtr:firstName><gtr:otherNames>Filip Johan Jules</gtr:otherNames><gtr:surname>Thielemans</gtr:surname><gtr:orcidId>0000-0002-5514-199X</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/523459CE-D7EE-4597-A646-523600B58309"><gtr:id>523459CE-D7EE-4597-A646-523600B58309</gtr:id><gtr:firstName>Steven</gtr:firstName><gtr:surname>Sourbron</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/635AE715-BD06-467A-8F5F-823DFEDCB5E3"><gtr:id>635AE715-BD06-467A-8F5F-823DFEDCB5E3</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Atkinson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=EP%2FP022200%2F1"><gtr:id>6DE0977A-6681-4A98-B97B-CD6E124FA13D</gtr:id><gtr:title>A framework for efficient synergistic spatiotemporal reconstruction of PET-MR dynamic data</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>EP/P022200/1</gtr:grantReference><gtr:abstractText>Magnetic resonance (MR) and radionuclide imaging using positron emission tomography (PET) are now essential in many areas of medical diagnosis, clinical research and drug development. The complementary information provided by PET and MR has recently lead to a new generation of dual-modality systems. Clinical applications of these devices are emerging in many priority areas for human health, including dementia, cardiology, and oncology. 
The previously established Collaborative Computational Project (CCP) for synergistic PET-MR reconstruction connects researchers working on sophisticated algorithms to estimate stacks of slices through the patient from the measured data. In this flagship project, we extend this work towards imaging of dynamic processes. Measuring the redistribution over time of contrasts agents or labelled molecules while taking organ movement into account provides considerable information on the biology, allowing extraction of parameters such as blood flow, receptor density and tissue elasticity.
By exploiting correlations between these parameters in both space and time, we can probe fast dynamic processes at higher accuracy than achievable in single modality imaging. This flagship will provide freely available software and methods to the community to accelerate research and development in this area.</gtr:abstractText><gtr:potentialImpactText>Biomedical imaging plays a key role in patient management, the assessment of new therapies and improved understanding of disease. PET-MR imaging is a newly developed technology that may provide new information that increases the effectiveness of medical imaging.

Patients
In the long-term, new imaging can benefit patients through more accurate and earlier diagnosis, and assessment of response to therapy. An early assessment of therapy response allows for a change in dose or management to match the response of the patient. This could lead to effective treatment occurring faster, or prevent prolonged unnecessary treatments with negative side-effects.

Health Service
Improved diagnosis and monitoring of disease and therapy response allows a more rational use of healthcare resources. Although imaging costs for PET-MR are of the order &amp;pound;1K/scan, the potential saving in costs of drugs or other interventions through better and earlier decisions is likely to far exceed this cost. In the UK, the NHS spends only about 7% of its budget on imaging.

Pharmaceutical Industry &amp;amp; Advanced imaging centres
The combined use of PET and MR offers the possibility of making measurements from PET and MR images more reliable and reproducible between different patients and imaging centres. Changes within a patient's images can be used as biomarkers for disease, potentially showing disease changes before symptoms are manifest. These quantitative imaging biomarkers are used in drug development and thus our methods will be useful to the Pharmaceutical industry and Advanced Imaging Centres. Improved quantification and accuracy will also improve statistical power in clinical trials, potentially allowing studies using smaller numbers of subjects or able to reach significant conclusions earlier. 

The clinical imaging industry
Impact is envisaged via the adoption of techniques we develop into the continuous improvement of commercial scanners by the main manufacturers (General Electric, Siemens and hilips). Industry representatives attend the Collaborative Computational Project (CCP) which is integrated with this project and our results and algorithms are freely available with a software licence that permits commercial use. Whilst aimed at dual-modality PET-MR systems, some of our techniques will be applicable to single modality systems which currently have a much larger market share.

The preclinical imaging industry
Major leading companies such as General Electric and Siemens who were originally leading the preclinical PET-MR imaging industry have disengaged due to lack of financial growth in the preclinical imaging market. Three main preclinical PET-MR scanner developers are currently leading the market: Mediso, Bruker and MRsolutions. These are relatively medium size enterprises which strive to resource image reconstruction due to the complexity and resource demands involved. It is harder for these small preclinical PET-MR companies to maintain and extend advanced software, which needs to include detailed modelling of physical and physiological phenomena. Thus, open access of reconstruction software will foster the preclinical PET-MR imaging sector.</gtr:potentialImpactText><gtr:fund><gtr:end>2020-05-15</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2017-09-16</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>523639</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">EP/P022200/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>